Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1995 May;54(5):366–374. doi: 10.1136/ard.54.5.366

Role of TNF alpha in the induction of antigen induced arthritis in the rabbit and the anti-arthritic effect of species specific TNF alpha neutralising monoclonal antibodies.

J Lewthwaite 1, S Blake 1, T Hardingham 1, R Foulkes 1, S Stephens 1, L Chaplin 1, S Emtage 1, C Catterall 1, S Short 1, A Nesbitt 1, et al.
PMCID: PMC1005596  PMID: 7794042

Abstract

OBJECTIVE--To investigate the role of tumour necrosis factor alpha (TNF alpha) in the development of antigen induced arthritis (AIA) in rabbits. METHODS--Monoclonal antibodies to rabbit TNF alpha were developed in rats and were used to detect TNF alpha in synovial fluid by enzyme linked immunosorbent assay and to localise it in tissue sections of synovium and cartilage from rabbits up to 21 days after induction of AIA. An antibody which neutralised TNF alpha activity in vitro was injected into rabbits to block TNF alpha action in vivo in AIA. Joint swelling, leucocyte infiltration into synovium and proteoglycan loss from cartilage were measured and compared with a control group, which were injected with sterile saline. RESULTS--Monoclonal antibodies to purified rabbit TNF alpha were prepared in rats and two were selected which were able to neutralise rabbit TNF alpha in a cytotoxicity bioassay. TNF alpha was detected in significant concentrations (21.7 (SE 0.5) pg/ml) in the arthritic joint fluid of rabbits with AIA only at one day after induction and it was then also sparsely localised in cells of the synovium, but from day 3 onwards it was localised more strongly in the deep zone of articular cartilage. Injection of anti-TNF monoclonal antibody R6 over three days into rabbits with AIA reduced joint swelling and leucocyte infiltration into joint fluid and decreased the expression of CD11b and CD18 on cells in the joint fluid. However, there was no significant reduction in the loss of proteoglycan from articular cartilage, although the joint fluid at three days contained a lower glycosaminoglycan content. The antibody R6 gave most effect at a dose of 0.6 mg/kg and there was no increase in its effectiveness at a fivefold greater dose (3.0 mg/kg). Treatment over 10 days gave a more complete suppression of joint swelling, but did not result in any less proteoglycan loss from cartilage. Treatment for five days with a 16 day follow up gave a significant reduction in swelling for several days beyond the treatment, but the swelling then slowly returned, until by day 21 there was no significant difference in joint swelling and there was also no recovery of cartilage proteoglycan content. A rabbit anti-rat immunoglobulin response was detected at 21 days, which may have limited the long term effectiveness of the antibody. CONCLUSIONS--In AIA in rabbits, TNF alpha was only detected in synovial fluid at one day after induction and there was only limited cellular localisation of TNF alpha in synovium and cartilage from three days. However, neutralising TNF alpha with a monoclonal antibody was effective in suppressing inflammatory changes in the joint during the acute onset of AIA, but it had little effect on the loss of proteoglycan from cartilage. The results suggest that blocking inflammation and synovitis with anti-TNF alpha may be more easily achieved than preventing damage to articular cartilage.

Full text

PDF
366

Images in this article

369Image
on p.369

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adams B., Regenass U., Cerletti N. An efficient method for the purification of tumor necrosis factor from rabbit serum. Lymphokine Res. 1987 Summer;6(3):203–214. [PubMed] [Google Scholar]
  2. Bertolini D. R., Nedwin G. E., Bringman T. S., Smith D. D., Mundy G. R. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature. 1986 Feb 6;319(6053):516–518. doi: 10.1038/319516a0. [DOI] [PubMed] [Google Scholar]
  3. Billingham M. E. Models of arthritis and the search for anti-arthritic drugs. Pharmacol Ther. 1983;21(3):389–428. doi: 10.1016/0163-7258(83)90062-1. [DOI] [PubMed] [Google Scholar]
  4. Bowen J. G., Crossley M. J., Hunneyball I. M. Disease-modifying anti-rheumatic drugs: strategies for screening. Pharmacol Ther. 1992 Dec;56(3):287–306. doi: 10.1016/0163-7258(92)90021-q. [DOI] [PubMed] [Google Scholar]
  5. Brennan F. M., Chantry D., Jackson A., Maini R., Feldmann M. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet. 1989 Jul 29;2(8657):244–247. doi: 10.1016/s0140-6736(89)90430-3. [DOI] [PubMed] [Google Scholar]
  6. Colcher D., Milenic D., Roselli M., Raubitschek A., Yarranton G., King D., Adair J., Whittle N., Bodmer M., Schlom J. Characterization and biodistribution of recombinant and recombinant/chimeric constructs of monoclonal antibody B72.3. Cancer Res. 1989 Apr 1;49(7):1738–1745. [PubMed] [Google Scholar]
  7. Consden R., Doble A., Glynn L. E., Nind A. P. Production of a chronic arthritis with ovalbumin. Its retention in the rabbit knee joint. Ann Rheum Dis. 1971 May;30(3):307–315. doi: 10.1136/ard.30.3.307. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Dayer J. M., Beutler B., Cerami A. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med. 1985 Dec 1;162(6):2163–2168. doi: 10.1084/jem.162.6.2163. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Di Giovine F. S., Nuki G., Duff G. W. Tumour necrosis factor in synovial exudates. Ann Rheum Dis. 1988 Sep;47(9):768–772. doi: 10.1136/ard.47.9.768. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Firestein G. S., Alvaro-Gracia J. M., Maki R., Alvaro-Garcia J. M. Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J Immunol. 1990 May 1;144(9):3347–3353. [PubMed] [Google Scholar]
  11. Flick D. A., Gifford G. E. Comparison of in vitro cell cytotoxic assays for tumor necrosis factor. J Immunol Methods. 1984 Mar 30;68(1-2):167–175. doi: 10.1016/0022-1759(84)90147-9. [DOI] [PubMed] [Google Scholar]
  12. Haranaka K., Satomi N., Sakurai A., Nariuchi H. Purification and partial amino acid sequence of rabbit tumor necrosis factor. Int J Cancer. 1985 Sep 15;36(3):395–400. [PubMed] [Google Scholar]
  13. Henderson B., Glynn L. E. Metabolic alterations in the synoviocytes in chronically inflamed knee joints in immune arthritis in the rabbit: comparison with rheumatoid arthritis. Br J Exp Pathol. 1981 Feb;62(1):27–33. [PMC free article] [PubMed] [Google Scholar]
  14. Henderson B., Hardingham T., Blake S., Lewthwaite J. Experimental arthritis models in the study of the mechanisms of articular cartilage loss in rheumatoid arthritis. Agents Actions Suppl. 1993;39:15–26. doi: 10.1007/978-3-0348-7442-7_2. [DOI] [PubMed] [Google Scholar]
  15. Henderson B., Pettipher E. R. Arthritogenic actions of recombinant IL-1 and tumour necrosis factor alpha in the rabbit: evidence for synergistic interactions between cytokines in vivo. Clin Exp Immunol. 1989 Feb;75(2):306–310. [PMC free article] [PubMed] [Google Scholar]
  16. Henderson B., Rowe F. M., Bird C. R., Gearing A. J. Production of interleukin 1 in the joint during the development of antigen-induced arthritis in the rabbit. Clin Exp Immunol. 1988 Dec;74(3):371–376. [PMC free article] [PubMed] [Google Scholar]
  17. Henderson B., Thompson R. C., Hardingham T., Lewthwaite J. Inhibition of interleukin-1-induced synovitis and articular cartilage proteoglycan loss in the rabbit knee by recombinant human interleukin-1 receptor antagonist. Cytokine. 1991 May;3(3):246–249. doi: 10.1016/1043-4666(91)90023-7. [DOI] [PubMed] [Google Scholar]
  18. Husby G., Williams R. C., Jr Synovial localization of tumor necrosis factor in patients with rheumatoid arthritis. J Autoimmun. 1988 Aug;1(4):363–371. doi: 10.1016/0896-8411(88)90006-6. [DOI] [PubMed] [Google Scholar]
  19. Ito H., Yamamoto S., Kuroda S., Sakamoto H., Kajihara J., Kiyota T., Hayashi H., Kato M., Seko M. Molecular cloning and expression in Escherichia coli of the cDNA coding for rabbit tumor necrosis factor. DNA. 1986 Apr;5(2):149–156. doi: 10.1089/dna.1986.5.149. [DOI] [PubMed] [Google Scholar]
  20. Keffer J., Probert L., Cazlaris H., Georgopoulos S., Kaslaris E., Kioussis D., Kollias G. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 1991 Dec;10(13):4025–4031. doi: 10.1002/j.1460-2075.1991.tb04978.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Lewthwaite J., Blake S. M., Hardingham T. E., Warden P. J., Henderson B. The effect of recombinant human interleukin 1 receptor antagonist on the induction phase of antigen induced arthritis in the rabbit. J Rheumatol. 1994 Mar;21(3):467–472. [PubMed] [Google Scholar]
  22. Maroudas A. Transport of solutes through cartilage: permeability to large molecules. J Anat. 1976 Nov;122(Pt 2):335–347. [PMC free article] [PubMed] [Google Scholar]
  23. Pettipher E. R., Henderson B., Edwards J. C., Higgs G. A. Effect of indomethacin on swelling, lymphocyte influx, and cartilage proteoglycan depletion in experimental arthritis. Ann Rheum Dis. 1989 Aug;48(8):623–627. doi: 10.1136/ard.48.8.623. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Pettipher E. R., Henderson B., Moncada S., Higgs G. A. Leucocyte infiltration and cartilage proteoglycan loss in immune arthritis in the rabbit. Br J Pharmacol. 1988 Sep;95(1):169–176. doi: 10.1111/j.1476-5381.1988.tb16561.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Pettipher E. R., Higgs G. A., Henderson B. Interleukin 1 induces leukocyte infiltration and cartilage proteoglycan degradation in the synovial joint. Proc Natl Acad Sci U S A. 1986 Nov;83(22):8749–8753. doi: 10.1073/pnas.83.22.8749. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Pober J. S., Gimbrone M. A., Jr, Lapierre L. A., Mendrick D. L., Fiers W., Rothlein R., Springer T. A. Overlapping patterns of activation of human endothelial cells by interleukin 1, tumor necrosis factor, and immune interferon. J Immunol. 1986 Sep 15;137(6):1893–1896. [PubMed] [Google Scholar]
  27. Ratcliffe A., Doherty M., Maini R. N., Hardingham T. E. Increased concentrations of proteoglycan components in the synovial fluids of patients with acute but not chronic joint disease. Ann Rheum Dis. 1988 Oct;47(10):826–832. doi: 10.1136/ard.47.10.826. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Ruff M. R., Gifford G. E. Purification and physico-chemical characterization of rabbit tumor necrosis factor. J Immunol. 1980 Oct;125(4):1671–1677. [PubMed] [Google Scholar]
  29. Saklatvala J. Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature. 1986 Aug 7;322(6079):547–549. doi: 10.1038/322547a0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Vilcek J., Palombella V. J., Henriksen-DeStefano D., Swenson C., Feinman R., Hirai M., Tsujimoto M. Fibroblast growth enhancing activity of tumor necrosis factor and its relationship to other polypeptide growth factors. J Exp Med. 1986 Mar 1;163(3):632–643. doi: 10.1084/jem.163.3.632. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Wilkinson L. S., Edwards J. C. Binding of antibodies raised against tumour necrosis factor alpha (TNF alpha) to blood vessels and macrophages in inflamed synovial tissue. Rheumatol Int. 1991;11(1):19–25. doi: 10.1007/BF00290246. [DOI] [PubMed] [Google Scholar]
  32. Wright E. M., Humphreys G. O., Yarranton G. T. Dual-origin plasmids containing an amplifiable ColE1 ori; temperature-controlled expression of cloned genes. Gene. 1986;49(3):311–321. doi: 10.1016/0378-1119(86)90367-7. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES